Granules India Limited (GRANULES) — Board Meeting

· NSE 🟡 Notable Neutral
📢 Key Event
Board approved Q1 FY2026 unaudited financial results and auditor review report.
🔄 What Changed
Approved unaudited standalone and consolidated Q1 FY2026 financial results; limited review report confirmed no material misstatement.
💡 Investor Takeaway
The company disclosed routine quarterly results with no new capital plans or strategic updates, indicating focus remains on compliance and operational stability.

Granules India approved unaudited standalone and consolidated financial results for Q1 FY2026 ending June 30, 2026, along with a limited review report from auditors. The board reviewed results, approved filings, and reaffirmed oversight of operations. No new strategic initiatives or capital actions were disclosed beyond routine compliance.

📄 View Original Announcement (PDF)

About Granules India Limited (GRANULES)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹18,242.81 Cr P/E: 37.2

View full GRANULES stock details →

📡 Get AI alerts when GRANULES files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track GRANULES — Free

📊 More GRANULES filings

See all GRANULES filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

📡 Get AI alerts when GRANULES files new disclosures

Track GRANULES filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track GRANULES — Free

Free account · 2 AI queries/day